New Application Note 021 on fragment kinetics

Our new Application Note 021 demonstrates how label-enhanced SPR expands the measurable kinetic space for fragments and small molecules into previously intractable regions. This provides new unique insights into lead optimization of small molecules and a novel understanding of how the dynamics of interactions involving weakly binding and/or low molecular weight compounds relate to protein function.

Please check out our Application Notes page for more info or order the new document directly from sales@episentec.com.

 

Research agreement with AstraZeneca / Press release

Episentec (Solna, Sweden) and AstraZeneca (Mölndal, Sweden) have signed a research collaboration agreement regarding the development and implementation of improved methodology for early screening of potential new drug molecules. The research project, aimed at an undisclosed drug target protein, will be utilizing the proprietary Label-Enhanced SPR biosensor technology of Episentec. Under the terms of the agreement, AstraZeneca will supply target protein and small molecules for screening, while Episentec will develop and implement new SPR-based screening methodologies. The goal of the project is to develop cost-efficient screening methods with higher sensitivity, higher specificity, and higher throughput than what is possible using today’s state-of-the-art technologies.

Anders Hanning, CEO of Episentec, comments: “We are very happy to get this opportunity to cooperate with AstraZeneca. We really believe that our Label-Enhanced SPR technology has the potential to take today’s SPR-based screening methods to a new level of performance.”

Stefan Geschwindner, Principal Scientist at AstraZeneca, adds: “Entering this collaboration with Episentec will bring us in a position to significantly expand the current application areas of SPR-based drug screening. Having found an experienced partner in that area makes us feel confident in achieving the goals of this collaboration, for the benefit of enabling unprecedented screening approaches as well as unlocking difficult target classes in the near future.”

For further information please contact:

Anders Hanning, CEO, Episentec anders.hanning@episentec.com +46 70 225 99 96

Stefan Geschwindner, Principal Scientist, Discovery Sciences, AstraZeneca R&D Mölndal stefan.geschwindner@astrazeneca.com +46 31 776 2197

About SPR-based drug screening: SPR (Surface Plasmon Resonance) is an optical biosensor method that is commonly used in the screening of potential new drug molecules. SPR is used to detect which molecules that bind to and interact with a specific disease target, usually a protein. SPR drug screening was pioneered by the Swedish company Biacore™, now part of GE Healthcare.

About Episentec: Episentec is a Swedish biotech company established in 2010 by scientists with a comprehensive experience in the development and application of biosensors. The aim of the company is to develop add-on tools that boost the performance of optical biosensor instruments. Episentec’s proprietary concept “Label-Enhanced SPR” substantially improves the performance of SPR-based biosensor instruments and expands their breadth of application. The company markets the Episentec™ range of dye reagents and EpiGrammer™ software for data evaluation, and also offers services for dye labelling of biomolecules and biosensor method development. For more information please visit: www.episentec.com

About AstraZeneca: AstraZeneca is a global, innovation-driven biopharmaceutical business that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of cardiovascular, metabolic, respiratory, inflammation, autoimmune, oncology, infection and neuroscience diseases. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. For more information please visit: www.astrazeneca.com

DiPIA conference, La Jolla, CA, 1-4 June 2014

We’re presenting a poster on ”Label-Free Interaction Analysis with Label-Enhanced Readout” at GE Healthcare’s DiPIA (Developments in Protein Interaction Analysis) conference in La Jolla, CA, 1-4 June 2014. Looking forward to meeting with lots of Biacore users in the US.

Don’t hesitate to contact us at sales@episentec.com to learn more about how high-performance label-free SPR analysis can be performed using our Label-Enhanced SPR technology.

 

Two new Application Notes

Application Note 019 describes competition-based screening and characterisation with label-enhanced SPR. Please note that in the competition format, the actual interaction between the analyte and the target is totally label-free while it’s only the readout that is label-enhanced.

Application Note 020 is a technology primer summarizing the basic aspects and applications of label-enhanced SPR.

Please check out our Application Notes page for more info or order the new documents directly from sales@episentec.com.

 

Drug Design & Medicinal Chemistry Conference, Berlin, 8-9 May 2014

We’re giving an oral presentation and presenting a poster on “Competition-based screening and characterization with Label-Enhanced SPR” at the Drug Design & Medicinal Chemistry Conference in Berlin, 8-9 May 2014. Check here for the full conference programme! Please don’t hesitate to contact us at the conference to discuss how we can help improve your SPR screens!

You are also welcome to contact us at info@episentec.com to book a meeting in advance.

Update on Technology & Applications

Our Technology & Applications web page has been thoroughly updated. We describe the functional principles behind label-enhanced SPR and how its strongly improved performance translates into benefits in different applications. Some interesting new references are also added.

Summary

The label-enhanced SPR technology of Episentec offers the following benefits:

  • Enhanced sensitivity: signal-to-noise ratio increased 100-fold.
  • Enhanced specificity: measurement is fully specific with respect to the dye label.
  • Compatibility with standard commercial SPR instruments.
  • Label-enhanced and label-free SPR simultaneously and in parallel.
  • Label-free analysis with outstanding sensitivity in competitive format.
  • Constant signal per bound molecule.
  • No bulk referencing needed.
  • Possibility to monitor two binders simultaneously.

Click here to check out the updated page!

Episentec – The Better Biosensor Company

 

Presenting B2 Dye Labels in Barcelona

We will participate in the Discovery Chemistry Congress in Barcelona, 18-19 February, and present a poster called “Competition-based screening and characterization with Label-Enhanced SPR”. The poster shows how the sensitivity of a Biacore™ instrument can be boosted 100-fold using our new B2 Series dye labels. Please stop by the poster for more information!

We have also published a new Application Note 018 describing highly sensitive kinetic analysis of small molecules on Biacore 2000 using the B2 Series dyes. Please don’t hesitate to contact us at sales@episentec.com for a copy of the Application Note, or for a Product Data Sheet or a Price List of our product range!

 

New Improved B2 Series of Dye Labels

We are launching the new, optically superior B2 series of dye labels for Biacore™ instruments. The new B2 series dyes give a further doubling of the sensitivity as compared to our old B1 series.

Please check out our Products & Services page for more product information!

We have also published a new Application Note 018 describing highly sensitive kinetic analysis of small molecules on Biacore 2000 using the B2 series dyes. Please don’t hesitate to contact us at sales@episentec.com for a copy of the Application Note, or for a Product Data Sheet or a Price List of our product range!

 

Season’s Greetings

The Episentec team would like to wish all customers, partners, and friends a Merry Christmas and a Happy New Year. We thank you all for interesting and fruitful contacts during 2013. We will kick-start 2014 with some really exciting product news, so please check back!